0114 232 9292 connect@medilink.co.uk


AlphaBiolabs, the Warrington-based innovative lab, has invested £400,000 in additional laboratory equipment to meet soaring demand for its non-invasive prenatal paternity test.

Its latest investment includes technology capable of new-generation DNA sequencing, and instrumentation which amplifies the visibility of DNA segments for analysis. 

In addition to anxious pregnant women seeking to learn the identity of their unborn baby’s father, the company has seen growth in demand from local authorities around Britain requiring court-admissible tests for use in child protection and custody cases.

The AlphaBiolabs test involves taking a blood sample from the mother and a mouth swab sample from the man. The DNA of the adults and the foetal DNA from the unborn baby, obtained from the mother’s bloodstream, are extracted at the lab, where the company’s team of geneticists examine these profiles.

Racher Davenport, Director at AlphaBiolabs, said: "In a climate where there is sensitivity over what happens to personal data, there had been a level of discomfort about sending samples outside of Europe, where there would be a certain loss of control over what happened to that data.

"Bringing this new technology to the UK market produces significant benefits to our customers in terms of convenience and cost. We are proud to be one of the few companies in the world to offer it."

To read more about this story, please click here.

Comments are closed.